| Description |
K7M2 wt-Luc is a bioluminescent derivative of the murine K7M2 osteosarcoma cell line, engineered to stably express a firefly luciferase reporter gene. The parental K7M2 cell line was established from ascites of a spontaneous osteosarcoma in a BALB/c mouse and is characterized by osteoblastic morphology and high metastatic potential, particularly to the lungs. K7M2 is one of the few syngeneic osteosarcoma models available in the BALB/c background, making it a valuable tool for studying osteosarcoma biology, tumor-immune interactions, and the evaluation of immunotherapy strategies in an immunocompetent host.
The stable luciferase integration in K7M2 wt-Luc enables sensitive, noninvasive bioluminescence imaging (BLI) of primary tumor growth and pulmonary metastatic spread in syngeneic BALB/c mice. Following administration of the luciferin substrate, the emitted signal correlates with viable tumor cell number, supporting longitudinal monitoring of tumor engraftment, metastatic colonization, and therapeutic response without invasive procedures at each time point. This makes K7M2 wt-Luc particularly suited for preclinical studies evaluating anti-tumor and anti-metastatic agents, checkpoint inhibitors, and combination treatment strategies in osteosarcoma.
K7M2 wt-Luc retains the biological and immunological properties of the parental K7M2 line, including expression of complement component C3 and Fc gamma receptor I (FcgRI), features that may influence interactions with the innate immune compartment. The luciferase reporter substantially enhances experimental flexibility and sensitivity for real-time tracking of tumor progression. Researchers should validate luciferase activity, growth kinetics, and metastatic behavior under their specific experimental conditions prior to large-scale in vivo use. |
